Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling

  • MAbs. 2014 May-Jun;6(3):774-82. doi: 10.4161/mabs.28612.
Stevan Shaw  1 ,  Tim Bourne  1 ,  Chris Meier  1 ,  Bruce Carrington  1 ,  Rich Gelinas  2 ,  Alistair Henry  1 ,  Andrew Popplewell  1 ,  Ralph Adams  1 ,  Terry Baker  1 ,  Steve Rapecki  1 ,  Diane Marshall  1 ,  Adrian Moore  1 ,  Helen Neale  1 ,  Alastair Lawson  1
Affiliations
  • 1. UCB Pharma; Berkshire, UK.
  • 2. Institute for Systems Biology; Seattle, WA USA.
PMID: 24670876 DOI: 10.4161/mabs.28612
Abstract

Interleukin-6 (IL-6) is a critical regulator of the immune system and has been widely implicated in autoimmune disease. Here, we describe the discovery and characterization of olokizumab, a humanized antibody to IL-6. Data from structural biology, Cell Biology and primate pharmacology demonstrate the therapeutic potential of targeting IL-6 at "Site 3", blocking the interaction with the signaling co-receptor gp130.

Keywords
IL-6; antibody; gp130; interleukin 6; neutralization; olokizumab; site 3; structure.
Products